We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 17, 2022

Finerenone Reduces CV and Kidney Outcomes Risk in Patients With Type 2 Diabetes and CKD

European Heart Journal

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Heart Journal
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Eur Heart J 2021 Nov 22;[EPub Ahead of Print], R Agarwal, G Filippatos, B Pitt, et al

Further Reading